Alopecia
- National Alopecia Areata Foundation: Patient Resources
- Alopecia Areata: Current Treatments and New Directions
- Janus kinase inhibitors for alopecia areata
- Treatment Options for Alopecia Areata in Children and Adolescents
- Ritlecitinib Prescribing Information
- Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double-blind, placebo-controlled trial
- Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial
- Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
- Defining Severity in Alopecia Areata: Current Perspectives and a Multidimensional Framework
- Development of the alopecia areata scale for clinical use: Results of an academic-industry collaborative effort
Atopic dermatitis
- Which Clinical Measurement Tools for Atopic Dermatitis Severity Make the Most Sense in Clinical Practice?
- Prevalence and burden of atopic dermatitis involving the head, neck, face, and hand
- New Perspectives in the Management of Chronic Hand Eczema: Lessons from Pathogenesis
- Validation of the Investigator Global Assessment of Chronic Hand Eczema (IGA–CHE): a new clinician reported outcome measure of CHE severity
- Efficacy and Safety of Dupilumab in the Treatment of Hand Eczema
- Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis
- Atopic hand dermatitis
- Atopic Dermatitis: Diagnosis and Treatment
- Emerging Systemic Treatments for Atopic Dermatitis
- Therapeutic education in atopic dermatitis
- Towards More Shared Decision Making in Dermatology: Development of Evidence-based Decision Cards for Psoriasis and Atopic Eczema Treatments
- Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials
- Dupilumab Provides Clinically Meaningful Responses in Children Aged 6–11 Years with Severe Atopic Dermatitis: Post Hoc Analysis Results from a Phase 3 Trial
- Atopic Dermatitis: Patient Materials
Facial Aesthetics
Pemphigus Vulgaris (PV)
- Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect
- Rituximab versus Mycophenolate Mofetil in Patients with Pemphigus Vulgaris
- Pemphigus Vulgaris
Prurigo Nodularis
- Prurigo Nodularis Signs and Symptoms – AAD Patient Resource
- 2022 Prurigo Nodularis Facts, Symptoms, Testing and Treatment – JAMA Patient Resource
- 2022 JAAD Health-related Quality of Life and Economic Burden of Prurigo Nodularis
- Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials (PRIME and PRIME2)
- Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study
- Efficacy and safety of oral nalbuphine extended release in prurigo nodularis: results of a phase 2 randomized controlled trial with an open-label extension phase
- Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis
- Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances
- Psychiatric Comorbidity and the Impact of Socioeconomic Status in Prurigo Nodularis
- Immunotargets and Immunotherapy for Prurigo Nodularis
- 2021 United States Expert Panel Consensus on the Diagnosis and Management of Prurigo Nodularis
- Pathophysiology, Diagnosis and Pharmacologic Treatment of Prurigo Nodularis
- Etiology, Clinical Diagnosis, Treatment Planning and Patient Education for Prurigo Nodularis
Psoriasis
- Time to Relapse After Discontinuing Systemic Treatment for Psoriasis: A Systematic Review
- Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis
- Psoriatic Disease Information for Parents/Caregivers
- Treatments for Psoriatic Disease – For Patients
- Understanding Psoriatic Disease – For Patients
- Psoriasis Clinical Guideline from the American Academy of Dermatology
- National Psoriasis Foundation
- Psoriasis Q & A – For Patients
